Trial Outcomes & Findings for The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis (NCT NCT00620126)

NCT ID: NCT00620126

Last Updated: 2019-11-13

Results Overview

Clinical disease activity was assessed using the Seo index. An activity index \<120 represents clinical remission, whereas scores of 121-150, 151-220, and \>221 correlate with mild, moderate, and severe disease respectively. The Seo index is sensitive to change, with a decrease in the index of 35 correlating with a clinical response.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

47 participants

Primary outcome timeframe

12 months

Results posted on

2019-11-13

Participant Flow

Participant milestones

Participant milestones
Measure
UC Home Automated Telemanagement
The UC HAT home unit consists of a netbook computer and an electronic weight scale. Participants answer questions regarding symptoms, side effects, adherence, and receive disease-specific education using the home unit. The home unit automatically transmits the results to the decision support server after each self-testing session. Participants completed self-testing weekly. Updated action plans are automatically transmitted to participant home units if certain criteria are met. If certain clinical conditions are met, email alerts are sent to the nurse coordinator. The coordinator reviews the information and if necessary consults the medical provider and the participant for management changes.
Best Available Care
The standard of care for participants in this study is modeled after the standard of care at our institution, and based on current evidence-based guidelines including comprehensive assessment, a guideline-concordant therapy plan, scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease-specific topics when appropriate. We expanded the care received by controls to make the groups more comparable. First, we provided the control group with all currently available educational fact sheets from the Crohn's and Colitis Foundation at the time of group allocation. Second, we provided the control group with individualized written action plans at the time of group assignment without reinforcement.
Overall Study
STARTED
25
22
Overall Study
COMPLETED
14
17
Overall Study
NOT COMPLETED
11
5

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intervention
n=25 Participants
UC Home Automated Telemanagement
Control
n=22 Participants
Best Available Care
Total
n=47 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Age, Categorical
Between 18 and 65 years
23 Participants
n=39 Participants
21 Participants
n=41 Participants
44 Participants
n=35 Participants
Age, Categorical
>=65 years
2 Participants
n=39 Participants
1 Participants
n=41 Participants
3 Participants
n=35 Participants
Age, Continuous
41.7 years
STANDARD_DEVIATION 13.9 • n=39 Participants
40.3 years
STANDARD_DEVIATION 13.9 • n=41 Participants
41.1 years
STANDARD_DEVIATION 14 • n=35 Participants
Sex: Female, Male
Female
15 Participants
n=39 Participants
15 Participants
n=41 Participants
30 Participants
n=35 Participants
Sex: Female, Male
Male
10 Participants
n=39 Participants
7 Participants
n=41 Participants
17 Participants
n=35 Participants
Region of Enrollment
United States
25 participants
n=39 Participants
22 participants
n=41 Participants
47 participants
n=35 Participants

PRIMARY outcome

Timeframe: 12 months

Clinical disease activity was assessed using the Seo index. An activity index \<120 represents clinical remission, whereas scores of 121-150, 151-220, and \>221 correlate with mild, moderate, and severe disease respectively. The Seo index is sensitive to change, with a decrease in the index of 35 correlating with a clinical response.

Outcome measures

Outcome measures
Measure
Intervention
n=25 Participants
UC Home Automated Telemanagement
Control
n=22 Participants
Best Available Care
Clinical Disease Activity (Seo Index)
122 Units
Standard Deviation 39.3
113.6 Units
Standard Deviation 28

PRIMARY outcome

Timeframe: 12 Months

Disease-specific quality of life was assessed using the IBD questionnaire (IBDQ). Scores for the IBDQ range from 32 to 224 with higher scores being associated with better quality of life. Score changes of 16 have been found to be significant changes when compared to baseline values.

Outcome measures

Outcome measures
Measure
Intervention
n=25 Participants
UC Home Automated Telemanagement
Control
n=22 Participants
Best Available Care
Quality of Life (IBDQ)
178.1 Units
Standard Deviation 32.1
187.3 Units
Standard Deviation 32.2

PRIMARY outcome

Timeframe: 12 Months

Adherence was assessed using the Morisky Medication Adherence Score, a 4 item survey in which participants self-report medication-taking behavior. Each question that is answered with a No receives a score of 1. The possible scoring range is therefore 0 to 4. Higher scores correlate with better medical adherence. For the purpose of evaluating percent of participants adherent to therapy, the variable was dichotomized to "Adherent" or "Non-adherent". Any response of Yes to one of the 4 items was scored as "Non-Adherent".

Outcome measures

Outcome measures
Measure
Intervention
n=25 Participants
UC Home Automated Telemanagement
Control
n=22 Participants
Best Available Care
Percentage of Participants Adherent to Therapy
57 Percentage of Participants
67 Percentage of Participants

Adverse Events

Intervention

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

PI

University of Maryland. Baltimore

Phone: 410-706-3387

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place